AZD6765 Severe Major Depressive Disorder (MDD) IV
Study identifier:D6702C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Medical condition
Major depressive disorder
Phase
Phase 2
Healthy volunteers
No
Study drug
AZD6765, Placebo
Sex
All
Actual Enrollment
152
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Oct 2008
Primary Completion Date: 01 Mar 2010
Study Completion Date: 01 Mar 2010
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD6765 100mg 100 mg intravenous (iv) once per dosing day | Drug: AZD6765 IV once per dosing day, multiple times during the treatment period |
| Experimental: AZD6765 150mg 150 mg iv once per dosing day | Drug: AZD6765 IV once per dosing day, multiple times during the treatment period |
| Placebo Comparator: Placebo Placebo once per dosing day | Drug: Placebo 0.9% saline IV once per dosing day multiple times during the treatment period |
Contacts
Investigators
Principal Investigator
Michael Castiglione
AstraZeneca
